116 citations
,
December 2003 in “Acta Dermato Venereologica” Iressa often causes skin issues like acne and dryness in lung cancer patients.
June 2026 in “Indian Journal of Postgraduate Dermatology” Rash from EGFRI treatment can indicate both side effects and treatment effectiveness.
17 citations
,
October 2024 in “Journal of the American Academy of Dermatology” Brepocitinib effectively reduces inflammation and improves symptoms in cicatricial alopecia with good safety.
February 2006 in “Inpharma Weekly” July 2026 in “Journal of Medicinal Chemistry” A new drug strategy improves hair loss treatment with better results and safety.
July 2026 in “Frontiers in Immunology” Ivarmacitinib may effectively treat complex atopic dermatitis and related hair loss.
February 2026 in “Frontiers in Immunology” Ivarmacitinib significantly improved hair regrowth in severe alopecia areata after tofacitinib was less effective.
January 2021 in “Journal of the European Academy of Dermatology and Venereology” PrEP doesn't increase STI risk in high-risk men, anti-androgen drugs may lower ICU admission for male COVID-19 patients, a 3-point injection is better for crow's feet, and the 'Geriatric-8' tool could help assess frailty in older skin cancer patients.
1 citations
,
September 2022 in “Nepal journal of dermatology, venereology & leprology” Apremilast shows promise for several skin conditions but needs more research.
9 citations
,
July 2022 in “Journal of Clinical Oncology” Oral paclitaxel plus encequidar improved tumor response and caused less neuropathy but more serious infections than intravenous paclitaxel.
5 citations
,
May 2024 in “Journal of Allergy and Clinical Immunology Global” Upadacitinib effectively improved severe atopic dermatitis and alopecia universalis in a 29-year-old man.
April 2024 in “Frontiers in pharmacology” Brepocitinib 30mg is most effective for moderate-to-severe alopecia areata, but ritlecitinib 50mg may offer a better balance of safety and effectiveness.
13 citations
,
April 2020 in “European Journal of Dermatology” Apremilast showed mixed results for treating severe alopecia areata.
July 2024 in “Journal of Investigative Dermatology” 2 citations
,
November 2025 in “British Journal of Pharmacology” Daprodustat, combined with PAβN, could be a new antibacterial treatment.
1 citations
,
April 2025 in “Skin Health and Disease” Abrocitinib is being evaluated for safety and effectiveness in treating moderate to severe atopic dermatitis.
22 citations
,
June 2002 in “Journal of Medicinal Chemistry” Compounds 15, 20, and 25 are strong inhibitors of human steroid 5α-reductase type 2.
February 2020 in “Bulletin of Experimental Biology and Medicine” Finasteride and GIZh-72 reduce inflammation, with GIZh-72 being more effective.
4 citations
,
October 2022 in “Current Urology” Platelet-rich plasma shows promise in reducing pain for bladder pain syndrome.
42 citations
,
November 2018 in “Archives of dermatological research” Apremilast was not effective in treating moderate-to-severe alopecia areata.
3 citations
,
May 2025 in “Carbohydrate Polymers” The new microneedle patch effectively treats alopecia areata with fewer side effects than oral medication.
June 2026 in “Journal of health economics and outcomes research” Ritlecitinib is more effective and cheaper than baricitinib for treating severe alopecia areata.
November 2021 in “World Family Medicine Journal /Middle East Journal of Family Medicine” Inclisiran is effective at lowering cholesterol.
79 citations
,
September 2018 in “Dermatologic therapy” Oral tofacitinib can significantly improve recalcitrant lichen planopilaris.
January 2025 in “Drug repurposing” New drug uses show promise but need more research.
September 2015 in “Photodiagnosis and Photodynamic Therapy”
May 2024 in “Journal of molecular structure” A new compound, 3a, effectively fights prostate cancer better than finasteride.
3 citations
,
January 2019 in “Indian Journal of Drugs in Dermatology” Certain cancer drugs can cause skin issues like rashes and itching.
10 citations
,
November 2014 in “Sexual medicine reviews” Effective, well-tolerated, and affordable treatments are needed for recurrent ischemic priapism.
36 citations
,
July 2005 in “Journal of Neuroendocrinology” Blocking certain brain processes reduces mating behavior in female rats.